Portions of this exhibit marked [*] are omitted and are requested to be treated confidentially. LICENSE AGREEMENTLicense Agreement • May 25th, 2010 • Furiex Pharmaceuticals, Inc. • Pharmaceutical preparations • California
Portions of this exhibit marked [*] are requested to be treated confidentially. MASTER DEVELOPMENT SERVICES AGREEMENTMaster Development Services Agreement • May 25th, 2010 • Furiex Pharmaceuticals, Inc. • Pharmaceutical preparations • North Carolina
THIS MASTER DEVELOPMENT SERVICES AGREEMENT (the “Agreement”) is made and entered into as of , 2010 (the “Effective Date”) by and between PPD DEVELOPMENT, LP, a Texas limited partnership, with its principal executive offices located at 929 North Front Street, Wilmington, North Carolina 28401 (“PPD”), and FURIEX PHARMACEUTICALS, INC., a Delaware corporation with its principal executive offices located at 3900 Paramount Parkway, Suite 150, Morrisville, North Carolina 27560 (“Sponsor”).
Portions of this exhibit marked [*] are omitted and are requested to be treated confidentially. OPTION AND LICENSE AGREEMENTOption and License Agreement • May 25th, 2010 • Furiex Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
THIS OPTION AND LICENSE AGREEMENT (the “Agreement”) is effective as of the 15th day of December, 2006 (the “Effective Date”) by and among PHARMACO INVESTMENTS, INC., a Delaware corporation having a place of business at 3151 South Seventeenth Street, Wilmington, North Carolina 28412 (referred to hereinafter as “PII”), a wholly owned subsidiary of Pharmaceutical Product Development, Inc., a North Carolina corporation having its principal place of business at 3151 South 17th Street, Wilmington, NC 28412 (“PPD”), and RANBAXY LABORATORIES LTD., a corporation incorporated, organized and operating under the laws of India and having a place of business at Plot 90, Sector 32 Gurgaon 122001 (Haryana), India (hereinafter “RBX”). PII and RBX are sometimes referred to herein individually as a “Party” and collectively as the “Parties.” PPD is a Party to this Agreement for the sole and limited purpose of agreeing to be bound by Section 12.19 of this Agreement.
CONSULTING AGREEMENTConsulting Agreement • May 25th, 2010 • Furiex Pharmaceuticals, Inc. • Pharmaceutical preparations • North Carolina
This CONSULTING AGREEMENT (the “Agreement”) is made and entered into this day of , 2010, by and between Furiex Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Fredric N. Eshelman (“Consultant”).
